NO20023607L - Kontraseptivpreparat for hannkjönn omfattende noretisterone - Google Patents

Kontraseptivpreparat for hannkjönn omfattende noretisterone Download PDF

Info

Publication number
NO20023607L
NO20023607L NO20023607A NO20023607A NO20023607L NO 20023607 L NO20023607 L NO 20023607L NO 20023607 A NO20023607 A NO 20023607A NO 20023607 A NO20023607 A NO 20023607A NO 20023607 L NO20023607 L NO 20023607L
Authority
NO
Norway
Prior art keywords
net
derivative
accordance
androgen
testosterone
Prior art date
Application number
NO20023607A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023607D0 (no
Inventor
Eberhard Nieschlag
Axel Kamischke
Michael Oettel
Alexander Ruebig
Ekkerhard Schillinger
Ursula-Friederike Habenicht
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20023607D0 publication Critical patent/NO20023607D0/no
Publication of NO20023607L publication Critical patent/NO20023607L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20023607A 2000-02-15 2002-07-30 Kontraseptivpreparat for hannkjönn omfattende noretisterone NO20023607L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50372900A 2000-02-15 2000-02-15
EP00200493 2000-02-15
PCT/IB2001/000188 WO2001060376A1 (en) 2000-02-15 2001-02-15 Male contraceptive formulation comprising norethisterone

Publications (2)

Publication Number Publication Date
NO20023607D0 NO20023607D0 (no) 2002-07-30
NO20023607L true NO20023607L (no) 2002-10-15

Family

ID=26071832

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023607A NO20023607L (no) 2000-02-15 2002-07-30 Kontraseptivpreparat for hannkjönn omfattende noretisterone

Country Status (26)

Country Link
EP (2) EP1267885B8 (https=)
JP (1) JP2003522795A (https=)
KR (1) KR20020086905A (https=)
CN (1) CN1423560A (https=)
AT (2) ATE355844T1 (https=)
AU (1) AU2001230447A1 (https=)
BG (1) BG107066A (https=)
BR (1) BR0108411A (https=)
CA (1) CA2398063A1 (https=)
CY (1) CY1106639T1 (https=)
CZ (1) CZ20022691A3 (https=)
DE (2) DE60142647D1 (https=)
DK (1) DK1267885T3 (https=)
EE (1) EE200200454A (https=)
ES (1) ES2282230T3 (https=)
HK (1) HK1049442B (https=)
HU (1) HUP0300128A3 (https=)
IL (1) IL151219A0 (https=)
MX (1) MXPA02007675A (https=)
NO (1) NO20023607L (https=)
PL (1) PL357185A1 (https=)
PT (1) PT1267885E (https=)
RU (1) RU2002124602A (https=)
SI (1) SI1267885T1 (https=)
SK (1) SK11602002A3 (https=)
WO (1) WO2001060376A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10234525A1 (de) * 2002-07-25 2004-02-05 Schering Ag Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
WO2004011663A2 (de) 2002-07-24 2004-02-05 Schering Aktiengesellschaft Mikrobiologische verfahren zur herstellung von 7alpha-substituierten 11alpha-hydroxysteroiden
AU2003251636B2 (en) * 2002-07-25 2009-10-22 Bayer Schering Pharma Aktiengesellschaft Composition containing an androgenous 11beta-halogen steroid and a progestational hormone, and male contraceptive based on said composition
JO2505B1 (en) * 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
CN101352443B (zh) * 2007-07-23 2011-01-12 中国科学院动物研究所 哺乳动物雄性不育剂
PL3750538T3 (pl) 2018-03-23 2024-11-25 Pharmajor International Niehormonalne sposoby męskiej antykoncepcji obejmujące (r) -sylodosynę
KR20250142811A (ko) * 2024-03-22 2025-09-30 주식회사 에아스텍 노르에티스테론 에난테이트 화합물의 암의 예방 또는 치료 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714420A1 (de) * 1976-06-01 1977-12-08 Int Pregnancy Advisory Service Antikonzeptionsmittel zur verabreichung an mann und frau in einer gemeinsamen verabreichungspackung
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
DE19650352A1 (de) * 1996-12-04 1998-07-30 Jenapharm Gmbh Oral wirksames Kombinationspräparat zur Kontrazeption für den Mann

Also Published As

Publication number Publication date
IL151219A0 (en) 2003-04-10
EP1666044B1 (en) 2010-07-21
ES2282230T3 (es) 2007-10-16
AU2001230447A1 (en) 2001-08-27
CA2398063A1 (en) 2001-08-23
RU2002124602A (ru) 2004-03-10
BG107066A (en) 2003-05-30
CZ20022691A3 (cs) 2003-01-15
BR0108411A (pt) 2003-03-11
DE60127103T2 (de) 2007-11-22
DK1267885T3 (da) 2007-07-09
CN1423560A (zh) 2003-06-11
KR20020086905A (ko) 2002-11-20
HK1049442A1 (en) 2003-05-16
EP1267885B8 (en) 2007-06-20
SI1267885T1 (sl) 2007-08-31
EP1267885B1 (en) 2007-03-07
EE200200454A (et) 2003-12-15
DE60142647D1 (de) 2010-09-02
EP1267885A1 (en) 2003-01-02
HK1049442B (en) 2007-06-15
CY1106639T1 (el) 2012-01-25
DE60127103D1 (de) 2007-04-19
SK11602002A3 (sk) 2003-03-04
ATE355844T1 (de) 2007-03-15
HUP0300128A3 (en) 2004-03-29
NO20023607D0 (no) 2002-07-30
MXPA02007675A (es) 2004-02-26
EP1666044A1 (en) 2006-06-07
WO2001060376A1 (en) 2001-08-23
JP2003522795A (ja) 2003-07-29
PT1267885E (pt) 2007-05-31
ATE474580T1 (de) 2010-08-15
PL357185A1 (en) 2004-07-26
HUP0300128A2 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
US20060142257A1 (en) Male contraceptive formulation comprising norethisterone
US7025979B2 (en) Male contraceptive formulation comprising norethisterone
US5891462A (en) Composition for transdermal administration of an estrogen
Swerdloff et al. Control of LH and FSH secretion in the male: evidence that aromatization of androgens to estradiol is not required for inhibition of gonadotropin secretion
US4177267A (en) Enhancing tissue penetration of physiologically active steroidal agents with DMSC
IL92007A (en) Healing and contraceptive preparations that are inserted through the skin and contain Gestudin
KR100577129B1 (ko) 안드로겐 스테로이드 화합물 및 그의 제조 및 이용 방법
WO2003075915A1 (en) 5-}2-hydroxy-3-`1-(3-trifluoromethylphenyl)-cyclopropyl!-propionylamino}- phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy
TW201322986A (zh) １８－甲基－６，７－亞甲基－３－氧基－１７－妊－４－烯－２１，１７β－羧內酯、包含該化合物之醫療製劑及其於治療子宮內膜異位症之用途
JP4716726B2 (ja) 新しいエトノゲストレルエステル
EP1390041A1 (en) Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
NO20023607L (no) Kontraseptivpreparat for hannkjönn omfattende noretisterone
DK2500062T3 (en) C-19 steroids to specific therapeutic applications,
EP0479867B1 (en) Compositions useful as contraceptives in males
GB1569286A (en) Oily depot solutions of gestagents for intramuscular injection
HK1090576A (en) Male contraceptive formulation comprising norethisterone
CN101332174A (zh) 二氢睾酮外用制剂及其药物用途
CA2289006A1 (en) Pregnan-3-ol-20-ones
EP1344776A1 (en) 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders
KR100481459B1 (ko) 에스트로겐,프로게스틴또는이의혼합물의경피투여용조성물
US20040259849A1 (en) 17Alpha-hydroxy-14Beta-steroids with hormonal effect
PL214858B1 (pl) Środek leczniczy na bazie noretysteronu lub jego farmaceutycznie dopuszczalnej pochodnej i estradiolu lub jego farmaceutycznie dopuszczalnej pochodnej

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application